A3P

Log in

The evolution of pharmacovigilance regulation at European level has led to significant changes in the electronic transmission of individual case safety reports (ICSRs) among the various actors in order to:

- rationalize the exchange of information,
- to ensure better monitoring of the safety of use of medicinal products,
- enrich the content of the exchanged data.

It is in this context that new features of EudraVigilance will be implemented by the EMA from 22 November 2017.

In this respect, a new guide for the electronic transmission of individual observations of adverse effects (ICSRs) is available on our website.

Information for pharmaceutical companies concerning the electronic transmission of individual pharmacovigilance observations

a3p-100pxhaut logo

 fren

Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )


  group    administrators A3P
    
& Project Managers

letter   newsletter A3P